Novo Nordisk A/S (NVO) - NYSE
  • Fri, Apr. 29, 11:14 AM
    • Novo Nordisk (NVO -0.6%) Q1 results (DKK million): Total Revenues: 27,212 (+8.0%); Diabetes and Obesity Care: 21,031 (+6.1%); Biopharmaceuticals: 6,181 (+14.8%).
    • Sales by Geography: U.S.: 13,730 (+14.3%); Europe: 5,016 (+0.8%); Intl: 3,516 (+2.7%); China: 2,875 (+1.0%); Pacific: 2,075 (+6.7%).
    • Sales by Business Segment: New-Generation Insulin: 626 (+131.0%); Modern Insulin (insulin analogues): 11,715 (+1.9%); Human Insulin: 2,725 (-5.9%); Victoza: 4,591 (+16.0%); Other: 1,374 (+15.0%).
    • Net Income: 9,455 (-4.3%); EPS: 3.71 (+22.8%); CF Ops: 7,475 (+82.1%).
    • 2016 Guidance: Sales growth: 5 - 9% (unch); Operating profit growth: 5 - 9% (unch); FCF: 35B - 38B from 36B - 39B.
    | Fri, Apr. 29, 11:14 AM
  • Fri, Apr. 29, 10:49 AM
    • Novo Nordisk (NYSE:NVO): Q1 EPS of DKK3.71
    • Revenue of DKK27.21B (+8.0% Y/Y)
    • Press Release
    | Fri, Apr. 29, 10:49 AM
  • Wed, Feb. 3, 10:16 AM
    • Novo Nordisk (NVO -6.3%) Q4 results (DKK million): Revenues: 28,876 (+17.5%); R&D Expense: 4,034 (+4.4%); SG&A: 9,203 (+18.8%); Operating Income: 11,125 (+21.5%); Net Income: 8,258 (+26.5%); EPS: 3.24 (+29.1%); CF Ops: 10,119 (+38.6%).
    • FY2015 results: Revenues: 107,927 (+21.5%); R&D Expense: 13,608 (-1.1%); SG&A: 32,169 (+20.2%); Operating Income: 49,444 (+43.3%); Net Income: 34,860 (+31.6%); EPS: 13.52 (+34.3%); Quick Assets: 3,542 (+134.7%); CF Ops: 38,287 (+20.8%).
    • 2016 Guidance: Sales growth: 5 - 9%; Operating profit growth: 5 - 9%; Net loss: ~DKK 1.3B; CAPEX: ~DKK 7.0B; FCF: DKK 36B - 39B.
    | Wed, Feb. 3, 10:16 AM | 3 Comments
  • Wed, Feb. 3, 7:20 AM
    • Novo Nordisk (NYSE:NVO): Q4 EPS of DKK3.24
    • Revenue of DKK28.88B (+17.4% Y/Y)
    | Wed, Feb. 3, 7:20 AM | 8 Comments
  • Oct. 29, 2015, 11:45 AM
    • Novo Nordisk (NVO -5.6%) Q3 results (DKK million): Revenues: 26,792 (+20.4%); COGS: 3,847 (+12.3%); R&D Expense: 3,289 (-10.0%); SG&A: 7,903 (+16.8%); Operating Income: 11,980 (+39.8%); Net Income: 8,383 (+29.0%); EPS: 3.26 (+32.0%); Marketable Securities: 2,024 (+34.1%).
    • 2015 Guidance: Sales growth: ~13% from ~14%; Operating profit growth: ~22% from ~23%; Net loss: ~DKK 5.6B from ~DKK 5.7B; FCF: DKK33 - 35B (unch).
    | Oct. 29, 2015, 11:45 AM | 10 Comments
  • Oct. 29, 2015, 7:31 AM
    • Novo Nordisk (NYSE:NVO): Q3 EPS of DKK3.26
    • Revenue of DKK26.79B (+20.4% Y/Y)
    | Oct. 29, 2015, 7:31 AM | 7 Comments
  • Oct. 28, 2015, 5:30 PM
  • Aug. 6, 2015, 10:09 AM
    • Novo Nordisk (NVO -3.2%) Q2 results (DKK million): Revenues: 27,059 (+25.1%); COGS: 3,859 (+5.1%); R&D Expense: 3,035 (-1.3%); SG&A: 8,062 (+26.9%); Operating Income: 12,482 (+42.9%); Net Income: 8,343 (+19.3%); EPS: 3.23 (21.4%); Quick Assets: 11,839 (-25.6%).
    • 2015 Guidance: Sales growth: ~14% from ~16%; Operating profit growth: ~23% from ~25%; Net Income: loss of ~DKK 5.7B from loss of ~DKK 6B; FCF: DKK33 - 35B from DKK32 - 34B.
    | Aug. 6, 2015, 10:09 AM | 5 Comments
  • Aug. 6, 2015, 8:27 AM
    • Novo Nordisk (NYSE:NVO): Q2 EPS of DKK3.23
    • Revenue of DKK27.06B (+25.1% Y/Y)
    | Aug. 6, 2015, 8:27 AM | 6 Comments
  • Apr. 30, 2015, 7:15 AM
    • Novo Nordisk (NYSE:NVO) Q1 results (DKK million): Total Revenues: 25,200 (+23.9%); Diabetes Care: 19,818 (+24.2%); Biopharmaceuticals: 5,382 (+22.8%); Operating Income: 13,857 (+72.5%); Net Income: 9,876 (+52.9%); Earnings/ADR: 3.02 (+24.3%); CF Ops: 4,106 (+0.9%).
    • Key product sales: Modern Insulin: 11,498 (+23%), NovoRapid: 4,682 (+20%) NovoMix: 2,744 (+16%), Levemir: 4,072 (+31%); Human Insulin: 2,897 (+13%); Victoza: 3,957 (+36%); Hemophilia: 2,734 (+21%); Hereof NovoSeven: 2,647 (+18%); Norditropin: 1,830 (+22%).
    • 2015 Guidance: Sales growth: ~16% from ~12%; Operating profit growth: ~25% from ~19%; Net Income: loss of ~DKK 6B from loss of ~DKK 5B; FCF: DKK32 - 34B from DKK29 - 31B.
    • Growth in actuals and guidance are "as reported" not in local currencies. Favorable exchange rates have and will contribute significantly to growth.
    • 1DKK = 0.15US$
    | Apr. 30, 2015, 7:15 AM | 3 Comments
  • Apr. 30, 2015, 5:30 AM
    • Novo Nordisk (NYSE:NVO): Q1 EPS of DKK3.02 vs. DKK2.43 in 1Q14
    • Revenue of DKK25.2B (+23.9% Y/Y)
    | Apr. 30, 2015, 5:30 AM
  • Jan. 30, 2015, 8:08 AM
    • Novo Nordisk (NVO +2.1%) Q4 results (DKK): Revenues: 24,585M (+13.3%); Gross Profit: 20,586M (+12.5%); Operating Income: 9,157M (+24.5%); Net Income: 6,529M (+7.9%); EPS: 2.51 (+10.6%).
    • FY2014 results (DKK) : Revenues: 88,806M (+6.3%); Gross Profit: 74,244M (+6.9%); Operating Income: 34,492M (+9.5%); Net Income: 26,481M (+5.2%); EPS: 10.07 (+7.7%); Quick Assets: 15,905M (9.9%); CF Ops: 31,962M(+23.2%).
    • FY2015 Guidance: (DKK): Sales growth: 6 -9% ; operating income growth: ~10%; net financials: ~5.0B; CAPEX: ~5.0B; FCF: 25B - 31B.
    | Jan. 30, 2015, 8:08 AM | 3 Comments
  • Jan. 30, 2015, 6:59 AM
    • Novo Nordisk (NYSE:NVO): Q4 EPS of DKK2.51.
    • Revenue of DKK24.59B (+13.3% Y/Y)
    | Jan. 30, 2015, 6:59 AM
  • Jan. 29, 2015, 5:30 PM
    | Jan. 29, 2015, 5:30 PM | 8 Comments
  • Oct. 30, 2014, 3:31 PM
    • Novo Nordisk (NVO +6.2%) Q3 results: (DKK M) Revenues: 22,249 (+8.5%); Gross Profit: 18,823 (+10.8%); Operating Income: 8,569 (+7.2%); Net Income: 6,500 (+1.3%); EPS: 2.47 (+3.3%); Quick Assets: 13,620 (-5.9%); CF Ops: 24,391 (+18.6).
    • 2014 Guidance (DKK): Sales growth: 7 -9% from 7 - 10%; operating income growth: ~10% (unch); net income/loss: ~(150M) from ~300M; CAPEX: ~4.0B (unch); FCF: ~25B (unch).
    | Oct. 30, 2014, 3:31 PM
Company Description
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes Care and Biopharmaceuticals segments. The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the... More
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: Denmark